SIP has seen an ever-increasing number of promising biomedicine businesses. It is now home to over 1,400 businesses of the kind which are jointly propelling a fast expansion of the biomedical ecosystem in the area.

Chinese pharmaceutical conglomerate Hengrui Medicine received the approval early this month from National Medical Products Administration (NMPA) of China for marketing Camrelizumab for Injection, a humanized anti-PD-1 monoclonal antibody that is applicable to treatment of patients with refractory hepatocellular carcinoma. Suzhou Shengdiya Biomedicine Co Ltd, a wholly-owned company of Hengrui Medicine in SIP, plans to make about 600,000 pieces of the new drugs this year.

 

BASECARE, a leading biomedicine company in SIP’s BioBAY, recently received from NMPA the approval for marketing its new testing kit for preimplantation genetic screening (PGS) aimed at detecting chromosome abnormalities of IVF (in-vitro fertilization) embryos. The testing kit, known as BasePGT-ATM, is reportedly the first product approved under the country’s “Green Channel” program which is designed to facilitate registration and marketing of innovative medical products, and the first registered product of its kind nationwide. 

Apart from that, many other biomedicine businesses have made remarkable achievements in their fields.